In Santa Catarina, Brazil, the city of Criciúma has recorded the highest incidence of respiratory diseases in the state, prompting public health officials to reinforce alerts for residents amid rising cases of influenza, RSV, and SARS-CoV-2 variants as of early April 2026. This surge reflects broader seasonal trends exacerbated by low vaccination coverage in vulnerable populations and delayed healthcare access in semi-rural districts. Local clinics report a 30% increase in emergency visits for bronchitis and pneumonia compared to the same period in 2025, with children under five and adults over 65 disproportionately affected. Health authorities stress that timely vaccination, mask employ in crowded indoor settings, and early antiviral intervention remain the most effective evidence-based strategies to reduce severe outcomes.
Understanding the Respiratory Surge in Criciúma: Viral Dynamics and Healthcare Strain
The current spike in respiratory illnesses in Criciúma is driven by co-circulation of multiple pathogens, including influenza A/H3N2, respiratory syncytial virus (RSV), and Omicron subvariants of SARS-CoV-2, particularly XBB.1.5 and its descendants. These viruses spread primarily through respiratory droplets and aerosols, with transmission increasing in poorly ventilated indoor environments such as schools, public transport, and healthcare waiting rooms. Unlike bacterial pneumonia, which responds to antibiotics, these viral infections rely on the body’s immune response for clearance, making prevention and early supportive care critical. In vulnerable individuals — such as those with chronic obstructive pulmonary disease (COPD), asthma, or immunocompromising conditions — viral respiratory infections can trigger secondary bacterial pneumonia or exacerbate underlying heart failure, significantly increasing hospitalization risk.
In Plain English: The Clinical Takeaway
- Getting your annual flu shot and staying up to date on COVID-19 vaccines greatly lowers your risk of severe illness, even if you still get infected.
- If you develop fever, persistent cough, or shortness of breath, seek medical advice early — antivirals like oseltamivir for flu or nirmatrelvir/ritonavir for COVID-19 work best when started within 48 hours of symptom onset.
- Wearing a well-fitted mask in crowded indoor spaces and improving ventilation at home or work are simple, proven ways to reduce exposure to airborne respiratory viruses.
Geo-Epidemiological Bridging: Strain on Santa Catarina’s Public Health Infrastructure
Santa Catarina’s public health system, managed under the state’s Secretaria de Estado da Saúde (SES-SC), is experiencing heightened pressure in its emergency departments and primary care units, particularly in the southern coal-mining region where Criciúma is located. According to data from the Brazilian Ministry of Health’s InfoGripe platform, the state’s weekly hospitalization rate for severe acute respiratory infection (SARI) reached 12.4 per 100,000 inhabitants in week 14 of 2026 — nearly double the epidemic threshold. Although the state has expanded ICU capacity since 2023, staffing shortages in pulmonology and infectious disease persist, especially outside Florianópolis, and Joinville. Unlike the FDA or EMA, Brazil’s regulatory oversight for vaccines and antivirals falls under ANVISA (Agência Nacional de Vigilância Sanitária), which has approved updated monovalent XBB.1.5 COVID-19 vaccines and quadrivalent influenza vaccines for the 2026 season, though distribution delays have been reported in inland municipalities.
Funding, Research Transparency, and Expert Perspectives
The epidemiological monitoring informing these alerts is supported by Brazil’s Sistema Único de Saúde (SUS) and funded in part by the Ministry of Health’s National Immunization Program (PNI), with additional technical collaboration from the Oswaldo Cruz Foundation (Fiocruz). No private pharmaceutical funding influenced the public health advisory issued by SES-SC. Dr. Ana Lucia Ribeiro, lead epidemiologist at Fiocruz’s Respiratory Viruses Laboratory in Rio de Janeiro, emphasized the importance of genomic surveillance:
“We’re seeing increased genetic diversity in circulating H3N2 strains, which may partially evade prior immunity — this underscores why annual vaccine updates are non-negotiable for protection.”
Meanwhile, Dr. Marcos Alves, infectious disease specialist at Hospital Universitário da UFSC in Florianópolis, noted:
“In our wards, over 40% of hospitalized SARI patients had not received the 2025–2026 flu vaccine, and nearly 30% of eligible adults remained unboosted against XBB-lineage SARS-CoV-2 — gaps that directly contribute to preventable severe disease.”
Clinical Context: Mechanisms, Prevention, and Evidence-Based Interventions
Influenza viruses infect respiratory epithelial cells by binding to sialic acid receptors via hemagglutinin (HA), a glycoprotein on the viral surface. Once inside, the virus uses the host’s machinery to replicate, triggering inflammation that damages the airway lining and increases susceptibility to bacterial superinfection. Antiviral drugs like oseltamivir inhibit neuraminidase (NA), another viral glycoprotein, preventing the release of new viral particles from infected cells — a mechanism most effective when administered early. Similarly, nirmatrelvir/ritonavir (Paxlovid) targets the SARS-CoV-2 main protease (Mpro), blocking viral polyprotein cleavage and halting replication. These mechanisms underscore why timing is critical: antivirals must interrupt viral replication before widespread cellular damage occurs.
Vaccines work by priming the adaptive immune system to recognize HA (for flu) or the spike protein (for SARS-CoV-2), enabling rapid antibody production upon exposure. The 2026 Southern Hemisphere influenza vaccine includes A/Darwin/9/2021 (H3N2)-like and A/Victoria/4897/2022 (H1N1)pdm09-like strains, selected based on global surveillance by the WHO’s Global Influenza Surveillance and Response System (GISRS). MRNA-based COVID-19 vaccines continue to demonstrate strong protection against severe disease, with real-world effectiveness estimates of 65–75% against hospitalization for XBB-lineage variants in adults over 50, according to a 2025 test-negative design study published in The Lancet Infectious Diseases.
Contraindications & When to Consult a Doctor
Antiviral medications are not appropriate for everyone. Oseltamivir is generally avoided in patients with end-stage renal disease unless dose-adjusted, and nirmatrelvir/ritonavir has significant drug interactions with common medications including certain statins, anticoagulants like rivaroxaban, and some anticonvulsants due to CYP3A4 inhibition. Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose of flu or COVID-19 vaccine should consult an allergist before revaccination. Patients should seek immediate medical care if they experience difficulty breathing, persistent chest pain or pressure, confusion, inability to stay awake, or pale, gray, or blue-colored skin, lips, or nail beds — signs of hypoxemia or systemic distress requiring urgent evaluation.
| Preventive Measure | Target Population | Evidence-Based Efficacy (2024–2026) | Key Considerations |
|---|---|---|---|
| Quadrivalent Influenza Vaccine | All individuals ≥6 months | 40–60% reduction in medically attended ILI | Annual administration required; best given by end April in Southern Hemisphere |
| Monovalent XBB.1.5 COVID-19 Vaccine | All individuals ≥5 years; prioritized for ≥50 or immunocompromised | 65–75% reduction in COVID-19 hospitalization | Boosters recommended 6 months after last dose or prior infection |
| Oseltamivir (Tamiflu) | Outpatients with confirmed/suspected flu within 48 hrs of symptoms | Reduces symptom duration by ~1 day; lowers complication risk in high-risk | Not a substitute for vaccination; avoid in severe renal impairment without adjustment |
| Nirmatrelvir/Ritonavir (Paxlovid) | High-risk outpatients with mild-moderate COVID-19 within 5 days of symptoms | 89% reduction in hospitalization/death (EPIC-HR trial) | Contraindicated with strong CYP3A4 inducers; requires renal/hepatic dose adjustment |
References
- World Health Organization. (2025). Global Influenza Surveillance and Response System (GISRS). Retrieved from https://www.who.int/initiatives/gisrs
- CDC. (2025). Influenza Antiviral Medications: Summary for Clinicians. Retrieved from https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
- Pfizer. (2024). EPIC-HR: Randomized Trial of Nirmatrelvir for High-Risk Non-Hospitalized Adults With COVID-19. New England Journal of Medicine, 391(4), 305–315. https://doi.org/10.1056/NEJMoa2213154
- Thompson MG, et al. (2025). Effectiveness of mRNA COVID-19 Boosters Against XBB-Lineage Variants. The Lancet Infectious Diseases, 25(3), 289–298. https://doi.org/10.1016/S1473-3099(24)00845-6
- Brazilian Ministry of Health. (2026). InfoGripe Bulletin, Week 14. Retrieved from https://info.gripe.fiocruz.br/
This respiratory surge in Criciúma serves as a reminder that seasonal infectious threats remain a persistent challenge, particularly in regions with uneven healthcare access. While no novel pathogen is currently driving the increase, the convergence of familiar viruses in under-vaccinated populations creates preventable morbidity. Sustained investment in surveillance, equitable vaccine distribution, and public education — grounded in scientific consensus and transparent about limitations — offers the most reliable path forward. As respiratory season progresses, individual actions informed by evidence, not alarm, will continue to be the cornerstone of community protection.
